Presentation is loading. Please wait.

Presentation is loading. Please wait.

Galapagos potentiator and correctors

Published byEtelka Fehér Modified over 5 years ago

Similar presentations

Presentation on theme: "Galapagos potentiator and correctors"— Presentation transcript:

1 Galapagos potentiator and correctors
Katja Conrath, PhD Therapeutic Area Head UK CF Conference, September 2016, Nottingham 7 September 2016

2 CF Program aim Develop a combination therapy
CFTR Combination Strategy Potentiator Correctors MSD1 MSD2 R NBD1 NBD2 GLPG1837 Early corrector Or C1 Late corrector Or C2 Two correctors with complementary MoAs

3 Galapagos potentiator and correctors
Pipeline AIM: develop triple combination therapy for treatment of most CF patients Discovery Preclinical Phase 1 Phase 2 Potentiator – GLPG1837 Potentiator – GLPG/ABBV2451 CFTR F508del corrector Early – GLPG/ABBV2222 CFTR F508del corrector Early – GLPG2851 CFTR F508del corrector Late – GLPG2737 CFTR F508del corrector Late – GLPGxxxx

4 Novel potentiators Activity and Efficacy on F508del and G551D CFTR
Identification of GLPG1837 GLPG1837, effects in primary patient cells Series 1 Series 2 GLPG1837 GLPG2451

5 GLPG1837 Phase 1 results MAD PK Day 14 Ctrough F508del/F508del Ctrough F508del/F508del Time (hours after first dosing) Day 1 Day 7 Day 14 Time after first dosing GLPG1837 was generally safe and well tolerated in healthy volunteers, with single doses up to 2000 mg and 14-day dosing up to 800mg b.i.d.

6 Organoids - EC50 = 15 nM, similar potency as on F508del CFTR
GLPG1837 Phase 2 study Two ongoing studies (Saphira 1 and 2) on G551D and S1251N CF patients, respectively Saphira 1 – G551D Saphira 2 – S1251N Organoids - EC50 = 15 nM, similar potency as on F508del CFTR Efficacy = 100% of VX-770 Primary cells - EC50 = 373 nM Efficacy = 180% of VX-770

7 Corrector Screening Campaigns Multiple approaches to identify correctors with distinct MoAs
Series identified Prioritized based on biological profile Prioritized based on chemical attractiveness 10 HTS 6 series progressed: - Early corrector mechanism series - 5 other corrector mechanism series CSE-HRP EA-MEM

8 Toolbox of assays CF Primary cells CFTR activity and current
complexity Ciliary beating ASL patch clamp Cell lines CFTR activity and current TECC & Ussing chamber Organoids Channel restoration, mutants YHA band B/C NBD AVI-tag Function, trafficking, folding Caveat on G442690 compound evolution Cell Surface expression libraries individual hits correctors

9 GLPG2222 – Early corrector Increase F508del Surface expression
Diseased cells control Treated with GLPG2222 Translation to primary patient cells (F508del/F508del) GLPG/ABBV2222 GLPG/ABBV2222

10 GLPG2222 – Early corrector GLPG2222 forms foundation for triple combination DR ‘Late corrector’ on DR GLPG2222 DR GLPG2222 on DR ‘Late corrector’

11 Late corrector – Series 1 Series progression
Cell Surface Expression In combination with Early corrector F508del/ F508del HBE cells TECC data GLPG2737 GLPG2737 700 600 500 400 300 200 100 % of GLPG GLPG1837 GLPG2222+GLPG1837 % of GLPG2222 correction GLPG GLPG1837 Normalized AUC to EC50 (nM)

12 CFTR modulators Correct as much F508del CFTR as possible
Surface expression – AVI-tagged F508del CFTR Getting close to Healthy cell status

13 CFTR modulators Correct as much F508del CFTR as possible
CFTR activity

14 Organoids Organoids from F508del/F508del patient Untreated Orkambi
GLPG Triple combination

15 Galapagos potentiator and correctors
Summary Discovery Preclinical Phase 1 Phase 2 Potentiator – GLPG1837 Potentiator – GLPG/ABBV2451 CFTR F508del corrector Early – GLPG/ABBV2222 CFTR F508del corrector Early – GLPG2851 CFTR F508del corrector Late – GLPG2737 CFTR F508del corrector Late – GLPGxxxx

16 Acknowledgements AbbVie Galapagos RFUMS Chris Tse Martin Andrews
Phil Kym Xueqing Wang Wenqing Gao Gao Yi Yi Yang Yihong Fan Ying Jia Arlene Manelli Ashvani Singh Andy Swensen Tim Vortherms Corina Balut Marlon Cowart Andrew Bogdan Steve Greszler Rob Koenig Bo Liu Eric Voight Clinton Yeung Gary Gintant Patricia Banfor Lee Preusser Rick Nelson Gerry Fox Pedro Quintana Diez David Geller Galapagos Martin Andrews Steven van der Plas Gert De Wilde Mathieu Pizzonero Nicolas Desroy Maarten Gees Anne-Sophie Wesse Ann van de Velde Moussa El-Abdellati Sara Musch Kim Carrein Niels Foolen Gregory Malfait Sebastien Dropsit Sebastien Martina Tom de Munck Caroline Joanesse Christel Menet Oscar Mamolliti Monica Borgonovi Florence Namour Luc Nelles Thierry Christophe Christine Guerin Ellen Voorspoels Herman De Kock Karen van de Wal Florence Namour Frederic Vanhoutte Olivier Van der Steen Didier Schils Emanuelle Wakselman Alain Monjardet Romain Gosmini Xavier Bock Dubravko Jelic Line Oste Pierre Deprez Jan van der Schueren Reginald Brys Piet Wigerinck Jack Chen John Fitzgerald Gayle O’Brien Jason Powell Jun Chen Murali Gopalakrishnan Rita Jain Jim Sullivan RFUMS Bob Bridges KUL Kris De Boeck Anabela Ramalho-Venancio UMC Utrecht Jeffrey Beekman University Utrecht Ineke Braakman Bertrand Kleizen Floor Peters

Download ppt "Galapagos potentiator and correctors"

Similar presentations

Galapagos: a new force in drug discovery Onno van de Stolpe – CEO IEX Beleggen in Biotech Dag May 20, 2006.

Galapagos: a new force in drug discovery Onno van de Stolpe – CEO IEX Beleggen in Biotech Dag May 20, 2006.
Global Pharmacometrics Influencing Early Portfolio Decision Making Using Pre-Clinical M&S: how early is too early and when is it too late? Peter A Milligan.

Global Pharmacometrics Influencing Early Portfolio Decision Making Using Pre-Clinical M&S: how early is too early and when is it too late? Peter A Milligan.
Gene therapy progress and prospects cancer. Gene Therapy Primary challenge for gene therapy – Successfully delivery an efficacious dose of a therapeutic.

Gene therapy progress and prospects cancer. Gene Therapy Primary challenge for gene therapy – Successfully delivery an efficacious dose of a therapeutic.
High-Throughput Screening Speeding Up CF Drug Discovery >10,000 Primary assays/day High-throughput screening CFTR Modulator Drug SAR based Medicinal Chemistry.

High-Throughput Screening Speeding Up CF Drug Discovery >10,000 Primary assays/day High-throughput screening CFTR Modulator Drug SAR based Medicinal Chemistry.
Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.

Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.
Drug discovery and development

Drug discovery and development
Screening and genome mining of polyether-producing strains in actinomycetes Minghao Liu, Hao Wang, Ning Liu, Jisheng Ruan and Ying Huang* State Key Laboratory.

Screening and genome mining of polyether-producing strains in actinomycetes Minghao Liu, Hao Wang, Ning Liu, Jisheng Ruan and Ying Huang* State Key Laboratory.
OLIVER BIRD COLLABORATIVE CENTRE NEWCASTLE UNIVERSITY Oliver Bird Collaborative Centre in Newcastle In 2003 we were one of five Centres awarded a grant.

OLIVER BIRD COLLABORATIVE CENTRE NEWCASTLE UNIVERSITY Oliver Bird Collaborative Centre in Newcastle In 2003 we were one of five Centres awarded a grant.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH.
The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
© Copyright 2015 Galapagos NV Poster available online at: www.glpg.com Defects in CFTR that result in Cystic Fibrosis can be broadly categorized into three.

© Copyright 2015 Galapagos NV Poster available online at: Defects in CFTR that result in Cystic Fibrosis can be broadly categorized into three.
METHODS Introduction Conclusions  The novel potentiator GP-2 is highly efficacious towards enhancing CFTR function following translational RT of PTCs,

METHODS Introduction Conclusions  The novel potentiator GP-2 is highly efficacious towards enhancing CFTR function following translational RT of PTCs,
P1586 THE FIRST JAK1-SELECTIVE INHIBITOR, FILGOTINIB, DISPLAYS SIMILAR MOLECULAR ACTIVITY IN THE GUT OF MICE WITH DSS-INDUCED COLITIS AND IN CULTURES OF.

P1586 THE FIRST JAK1-SELECTIVE INHIBITOR, FILGOTINIB, DISPLAYS SIMILAR MOLECULAR ACTIVITY IN THE GUT OF MICE WITH DSS-INDUCED COLITIS AND IN CULTURES OF.
Using additivity and bliss analysis to categorize corrector-corrector interactions Tim Vortherms*, Anne-Sophie Wesse, Arlene Manelli*, Andrew Swensen*,

Using additivity and bliss analysis to categorize corrector-corrector interactions Tim Vortherms*, Anne-Sophie Wesse, Arlene Manelli*, Andrew Swensen*,
© Copyright 2015 Galapagos NV Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GLPG1837 in healthy volunteers F.P. Vanhoutte 1, M-H.

© Copyright 2015 Galapagos NV Safety, tolerability and pharmacokinetics of a novel CFTR potentiator GLPG1837 in healthy volunteers F.P. Vanhoutte 1, M-H.
POTENTIATORS: HOW DO THEY IMPACT THE FATE OF CFTR DURING BIOGENESIS? 1 Cellular Protein Chemistry, Faculty of Science, Utrecht University, Padualaan 8,

POTENTIATORS: HOW DO THEY IMPACT THE FATE OF CFTR DURING BIOGENESIS? 1 Cellular Protein Chemistry, Faculty of Science, Utrecht University, Padualaan 8,
VR-23, a New Anticancer Drug Developed in Northern Ontario Hai-Yen Vu, PhD and Hoyun Lee, PhD.

VR-23, a New Anticancer Drug Developed in Northern Ontario Hai-Yen Vu, PhD and Hoyun Lee, PhD.
“Journey of a Drug” From Test Tube TO Prescribing Physician.

“Journey of a Drug” From Test Tube TO Prescribing Physician.
New Developments in Cystic Fibrosis

New Developments in Cystic Fibrosis
26th April 2016, BioTrinity - London

26th April 2016, BioTrinity - London

Similar presentations

Ads by Google